How Does Molnupiravir Work? Mechanism of Action Explained in Plain English

Molnupiravir doesn't fight COVID-19 the way most people expect an antiviral to work. It doesn't block the virus from entering your cells. It doesn't neutralize it with antibodies. Instead, it uses a clever trick: it makes the virus copy itself — but with so many errors that the copies are defective and can't infect anything.

Here's exactly how that works — in plain English.

First: How Does COVID-19 Spread Through Your Body?

SARS-CoV-2 (the virus that causes COVID-19) is an RNA virus — its genetic blueprint is made of RNA instead of DNA. To multiply and spread through your body, the virus needs to:

Enter one of your cells.

Use your cell's machinery to copy its own RNA — a process handled by a viral enzyme called RNA-dependent RNA polymerase (RdRp).

Release thousands of copies of itself into your body, infecting more cells and spreading the disease.

Molnupiravir attacks Step 2 — the copying process.

What Is a Prodrug?

Molnupiravir is a prodrug — it is not active in the form you swallow it. When you take the capsule, your body's enzymes quickly convert it into its active form: a molecule called N4-hydroxycytidine (NHC). This active molecule is then taken up by cells and converted again into NHC-triphosphate (NHC-TP), which is the form that actually stops the virus.

The Clever Trick: Viral Error Induction (Lethal Mutagenesis)

NHC-TP looks like one of the normal "letters" in RNA — specifically, it resembles cytidine (C). When the COVID-19 virus's RdRp enzyme is copying viral RNA, it accidentally uses NHC-TP instead of the real cytidine.

Here's where the trick gets clever: NHC-TP can "swap" between two different shapes. Sometimes it acts like cytidine (C) — and sometimes it acts like uridine (U), a completely different building block. The virus's copying enzyme can't tell the difference, so it keeps incorporating these imposter molecules.

Each time the virus copies itself, it makes errors where NHC-TP was inserted. Unlike many RNA mistakes, the virus's proofreading enzyme (its exonuclease) does not catch and fix NHC-TP errors — so the mistakes accumulate.

After enough copying cycles, the viral genome becomes so riddled with errors that the new viral copies are incompetent — they cannot infect cells or replicate further. Scientists call this process "lethal mutagenesis" or "error catastrophe."

Why Doesn't Molnupiravir Harm Your Own DNA?

This is one of the most common concerns about molnupiravir, and it's worth addressing directly. NHC-TP is incorporated by viral RdRp enzymes — enzymes that the virus brings into the cell. Human DNA polymerases (the enzymes that copy your own DNA) do not efficiently use NHC-TP, so your own genetic material is not affected in the same way.

That said, there is a theoretical risk of mutagenic effects, which is why the drug is not used in pregnancy (boxed warning) and not used in children (whose developing bone and cartilage may be more vulnerable). The FDA's review of the drug's safety data in the standard 5-day adult course supported authorization.

How Is Molnupiravir Different from Paxlovid?

Paxlovid works completely differently — it inhibits a different viral enzyme called protease (3CL protease), which the virus needs to assemble its proteins. Paxlovid blocks the assembly line; molnupiravir corrupts the blueprint.

Key practical difference: Paxlovid contains ritonavir, which interacts with many medications. Molnupiravir has no known drug-drug interactions — a major advantage for patients on complex medication regimens.

What About Viral Resistance?

Molnupiravir has a high barrier to resistance. Because it works by causing widespread random mutations (not blocking a specific single enzyme site), the virus cannot easily evolve resistance to it through a single mutation — it would need to simultaneously fix many different errors.

However, research published in 2023 found that molnupiravir's mutation-inducing mechanism may contribute to circulating SARS-CoV-2 genetic variation — meaning that in some cases, the mutated viruses may continue circulating rather than dying. This is an area of ongoing scientific study.

How Quickly Does Molnupiravir Work?

Molnupiravir reaches peak plasma concentration about 1.5 hours after taking it on an empty stomach. The active NHC-TP begins working in cells shortly after. Most patients notice symptomatic improvement within 2–3 days of starting treatment. Clinical data from the MOVe-OUT trial showed viral RNA clearance was accelerated compared to placebo.

Does It Work Against All COVID Variants?

Because molnupiravir targets the RdRp enzyme — which is highly conserved across SARS-CoV-2 variants — it retains activity against all major variants, including Omicron and its subvariants. In vitro studies confirm activity against Alpha, Beta, Gamma, Delta, and Omicron. This is another advantage over antibody therapies, which can lose effectiveness when the virus mutates.

For a full overview of molnupiravir, read What Is Molnupiravir? Uses, Dosage, and What You Need to Know in 2026.